Antimicrobials
Daptomycin

Daptomycin

Low
N/A

Dosing

General Information

Decision to use daptomycin should made with ID consultation

Baseline CK; then every 7 days Discontinue if: Signs/symptoms of myopathy and CK >1000 U/L; or if increased CK >2000 U/L

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC≥2) and VRE including endovascular infection

  • GI side effects common
  • Rash
  • Phlebitis
  • Increased INR
  • Myopathy including rhabdomyolysis
  • Eosinophilic pneumonia (rare)

Statins and fibrates - Additive risk of myopathy unclear. Infections are pro-inflammatory states and statins should not be routinely discontinued during daptomycin use.

Higher doses used for endovascular infection.

Recommend Infectious Disease Consult.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

Urine penetration: Therapeutic

Lung penetration: Inactivated by alveolar surfactants; appropriate for use in treatment of septic pulmonary emboli

CSF penetration: Poor